Home
Emergent BioSolutions EBS paid Forbes-Tate $20K for lobbying in Q3 2023 · Health Issues, Budget
Trade details
- Type
- Lobbying report
- Amount
- $20,000
- Quarter
- Q3 2023
- Client
- Emergent Biosolutions
- Reported
- 23/10/17
Down 66.7% from last quarter
What else happened in Emergent BioSolutions around then
Filed or reported within 30 days of the trade day · 23/08/31~23/10/30Emergent Biosolutions's other lobbying reports
- Emergent Biosolutions
LobbyingEmergent BioSolutions
LobbyingEmergent BioSolutions
EBS
$70K
$70K
Reported 07/19
for Q2
- Emergent Biosolutions
LobbyingEmergent BioSolutions
LobbyingEmergent BioSolutions
EBS
$40K
$40K
Reported 07/15
for Q2
- Emergent Biosolutions
LobbyingEmergent BioSolutions
LobbyingEmergent BioSolutions
EBS
$510K
$510K
Reported 07/14
for Q2
- Emergent Biosolutions
LobbyingEmergent BioSolutions
LobbyingEmergent BioSolutions
EBS
$50K
$50K
Reported 07/08
for Q2
- Emergent Biosolutions
LobbyingEmergent BioSolutions
LobbyingEmergent BioSolutions
EBS
$70K
$70K
Reported 04/20
for Q1